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Introduction
Malignant peripheral nerve sheath tumors (MPNSTs) are ex-
ceedingly rare in patients without a history of neurofibroma-
tosis - a group of genetic disorders of the nervous system that 
cause tumors to grow on nerves and other tissues.
1 MPNSTs 
of the spinal accessory nerve may involve the nerve at vari-
ous points along its course from the cervical segment of the 
spinal cord to the trapezius muscle.
2-7 The various segments 
of the nerve are classified as cisternal, foraminal, and intra-
sternomastoid.
4,6 The extracranial portion of the nerve, spe-
cifically its intrasternomastoid segment, is the least common 
location of the nerve to be involved by a peripheral nerve 
sheath tumor,
4-6 and metastasis to the brain from this location 
has not been reported. We report here a patient with a well-
circumscribed mass in the brain parenchyma, which was a 
metastatic lesion of an MPNST of the intrasternomastoid seg-
ment spinal accessory nerve - a unique presentation of an ex-
ceeding rare tumor.
Case Report
The patient is a 54-year-old white woman previously diag-
nosed as having an MPNST of the right spinal accessory 
nerve. Confirmation of the tumor was made by tissue biopsy 
of a mass located in the right supraclavicular region approxi-
mately 2 years ago. During her initial presentation in July 
2009, we performed a wide excision of the mass and a senti-
nel lymph node biopsy of the right neck and axillary lymph 
nodes. Using a marking pen, we drew an elliptical incision 
around the mass to create a 2-cm margin from its palpable 
edge. In total, we excised an ellipse of tissue with diameters of 
15×10 cm. After resection, the patient received four cycles of 
radiation therapy to the right supraclavicular region. She had 
been in good health since the diagnosis, and her outpatient 
medical regimen consisted only of a proton-pump inhibitor 
for treatment of gastroesophageal reflux disease. However, 
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nearly 1 month before admission, the patient became symp-
tomatic and presented to the emergency department with com-
plaints of headache, visual disturbances, loss of short-term 
memory, and ataxic gait. In addition, she complained of visual 
loss on rightward gaze and loss of balance with head move-
ment. 
On presentation to the emergency department, her vital 
signs remained within normal limits. Physical examination 
revealed evidence of both long- and short-term memory defi-
cits as well as a right visual field cut, and results of laborato-
ry studies including an electrocardiogram were all within 
normal limits. However, radiographic examination of the 
brain by contrast-enhanced magnetic resonance imaging 
(MRI) revealed a well-defined 2.2×2.2×2.2 cm, homoge-
neously enhancing mass in the left parieto-occipital region 
surrounded by significant vasogenic edema. There was also 
evidence of mass effect, culminating in a 1-cm midline shift 
to the right; these findings were not present on an MRI ob-
tained 5 months prior to admission (Fig. 1). The patient was 
subsequently admitted to the neurological intensive care unit 
(ICU) for neurological monitoring, and a neurosurgical con-
sultation was obtained. As part of an evaluation for distant 
metastases, a contrast-enhanced CT scan of the chest revealed 
a new 1.1-cm nodule in the left lower lobe and a stable 0.4-cm 
nodule in the same location (Fig. 2). The patient’s course in 
the neurological ICU was remarkable for only one episode 
of hypertension on the second day. Routine laboratory stud-
ies were obtained and were within normal limits.
On day 7 in the neurological ICU, we performed a cranioto-
my with complete removal of the mass. A biopsy of the mass 
was obtained in the operating room, and a pathologist con-
firmed the diagnosis of a metastatic nerve sheath tumor (Fig. 
3). Histopathological findings revealed malignant tissue with 
poorly defined cellular and cystic components. The malignant 
cells expressed vimentin and S-100 but not glial fibrillary 
acidic protein, neurofilaments, melanoma marker, actin, 
smooth muscle antibody, pan-cytokeratin, or Melan-A. Con-
firmation of the brain tumor as a metastatic lesion of the orig-
inal tumor of the spinal accessory nerve was based both on 
findings of immunohistochemical tests and the nearly identi-
cal morphological characteristics shared by the 2 tumors.
On postoperative day 1, the patient reported marked im-
provement in vision, speech, and memory, although not to 
baseline level. It is noteworthy that the brain lesion was consid-
ered to be a new tumor, because the results of an MRI scan of 
the brain obtained 5 months before this admission were within 
normal limits (Fig. 1B). The patient’s postoperative course 
was uneventful and included a 2-week course of radiation 
therapy. On postoperative day 6, she was transferred to the on-
cology floor for further treatment.
Discussion
To our knowledge, this is the first documented case of an 
MPNST arising from an extracranial segment of the spinal 
accessory nerve and metastasizing to the brain.
1-4 
Kurokowa et al.
4 described the first case of a spinal accesso-
ry schwannoma arising in the fourth ventricle in a 50-year-old 
man presenting with neck pain after trauma. Physical examina-
tion findings from the patient described in their report were not 
consistent with cranial nerve involvement; and they did not re-
port upper or lower extremity weakness or gait disturbance. The 
Fig. 1. A: Initial MRI performed in 2009 as part of staging for pe-
ripheral nerve sheath tumor. T1 weighted axial image post gadolin-
ium injection was negative for abnormal intracranial enhancement. 
B: Repeat MRI performed August 2010 on admission to neurologi-
cal intensive care unit. T1 weighted axial image post gadolinium in-
jection revealed 2.2×2.2×2.2 cm, well-circumscribed, homoge-
neously enhancing lesion identified in the left occipital lobe with 
extensive vasogenic edema. A midline shift to the right of approxi-
mately 1 cm with subfalcine herniation is evident. Mass effect is 
identified on the occipital horn of the lateral ventricle.
B   A  
Fig. 2. Contrast-enhanced CT scan of the chest at the time of ad-
mission to the neurological intensive care unit. Scan revealed a new 
1.1-cm left lower lobe solid nodular density adjacent to the lateral 
basilar segment artery and bronchus. A stable 0.4-cm nodule was 
seen peripheral to the left lower lobe.Sheikh OA et al.
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authors speculate that the accessory nerve tumor initially in-
volved the intracisternal segment of the nerve and subsequent-
ly grew into the fourth ventricle. In their review of the literature, 
they identified only 30 cases of accessory schwannomas unas-
sociated with neurofibromatosis published since 1975;
4 how-
ever, only two of these cases presented with a schwannoma of 
the nerve in the region of the neck (i.e., intrasternomastoid por-
tion), and neither of these cases presented with metastasis to 
the brain.
6,7 Moreover, in both cases, no focal neurological def-
icits were reported on physical examination.
6,7
MPNSTs are sarcomas originating from tissues of mesenchy-
mal origin, i.e., peripheral nerves or cells of the nerve sheath 
such as Schwann cells or perineural cells.
8 Hence, the terms 
malignant schwannoma, neurogenic sarcoma, or neurofibrosar-
coma are used interchangeably.
8-10 MPNST tumors commonly 
present a diagnostic challenge to pathologists because they arise 
from different types of cells (Schwann cells, fibroblasts, peri-
neural cells) and may therefore produce a variable histological 
appearance.
10 According to Geller and Gebhardt, at least one 
of the following has to be present for the diagnosis of MPNST: 
“1) a tumor arising from peripheral nerves; 2) a tumor arising 
from existing benign or other MPNST; or 3) a tumor that dis-
plays histological features of Schwann cells or perineural dif-
ferentiation as revealed by immunohistochemical analysis or 
electron microscopic examination.”
10 MPNSTs comprise almost 
10% to 12% of all soft tissue sarcomas, which are primarily 
associated with neurofibromatosis type 1 with a gene muta-
tion of the same name; however, they can arise sporadically 
without neurofibromatosis type 1, in almost 50% of patients, 
as in the case of our patient. A strong relationship exists be-
tween a history of radiation therapy and MPNST.
11,12 This tu-
mor has a high percentage of recurrence at the primary or new 
site, and metastasis to the lungs, bones, or intra-abdominal or 
intrathoracic organs is not uncommon. However, metastasis to 
the brain is highly unusual; only a handful of cases have been 
reported to date, making this case of an MPNST of the spinal 
accessory nerve a novel finding.
MPNST usually occurs in patients between the ages of 20 
to 50, but in an extreme case, it has been reported in an 11- 
month-old patient.
9,10 These tumors present with pain, palpa-
ble mass, hemiparesis, or paresthesias, usually in a dermato-
mal pattern. Not surprisingly, an MPNST affects large peri-
pheral nerves such as the sciatic nerve or the brachial or sacral 
plexus. Large nodular lesions in large peripheral nerves or plex-
us have greater potential for malignant transformation.
10 Diag-
nosis and staging are usually done by surgical resection and bi-
opsy. MRI and CT scans show the extent of the lesion and the 
distant metastasis and are therefore valuable in staging the le-
sion. Large tumors (>5 cm), invasion of fat planes, heterogene-
ity, ill-defined margins, and edema surrounding the lesion sug-
gest an MPNST.
13,14 
According to Geller and Gebhardt, staging of soft tissue sar-
comas is dependent on a number of factors including histolog-
ical grade, tumor size, tumor depth, and whether or not metas-
tases have been identified.
10 In patients without detectable 
metastases, histological grade, tumor size, and tumor depth ap-
pear to predict subsequent metastasis.
10 In addition, tumor stag-
ing is also based on the findings of imaging studies, which are 
frequently needed to define location and extent of disease.
10,15 
It is postulated that metastasis to the brain, though rare, hap-
pens by the following three routes:
7 1) direct invasion; 2) he-
matogenous spread; 3) dissemination through the cerebrospi-
nal fluid.
16 It is not known whether the 9-mm pulmonary nodule 
identified on CT scans of the chest in the present case was a 
metastatic lesion, but by inference it raises the possibility of 
metastasis to the brain by a hematogenous route.
16 
It remains unclear why the brain is an infrequent site of me-
tastasis. Although negative surgical margins and location of the 
tumor are considered important prognostic factors, patients 
frequently have metastases from negative surgical margins at 
the primary lesion site, as in the case of our patient. Radiation 
is still the mainstay of therapy because of high local recurrence 
and pulmonary involvement, and the role of chemotherapy in 
the treatment of this tumor still needs to be firmly established. 
B   A  
Fig. 3. A: Photomicrograph of an S-100 immunohistochemically stained slide (magnification ×400) of tissue from the original tumor, which con-
firms the tumor as an MPNST. B: Photomicrograph of an H & E slide (magnification ×400) of tissue from the cerebral mass. It shows a cellular 
neoplasm exhibiting storiform architecture with moderate nuclear atypia. Other areas show increased mitotic activity and necrosis. The diagno-
sis of MPNST was based on expression of similar immunohistochemical staining and nearly identical morphological characteristics shared be-
tween the original tumor and the metastatic tumor.Malignant Nerve Sheath Tumor 
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The overall prognosis for a patient with this tumor is poor be-
cause most of the patients succumb to pulmonary complica-
tions; the 5-year survival rate ranges from 16% to 52%.
16 
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